HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.9%

Neg 0% Neu 92.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.